Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism

Surgery. 2022 Jan;171(1):47-54. doi: 10.1016/j.surg.2021.05.056. Epub 2021 Jul 21.

Abstract

Background: Preoperative parathyroid imaging guides surgeons during parathyroidectomy. This study evaluates the clinical impact of 18F-fluorocholine positron emission tomography for preoperative parathyroid localization on patients with primary hyperparathyroidism.

Methods: Patients with primary hyperparathyroidism and indications for parathyroidectomy had simultaneous 18F-fluorocholine positron emission tomography imaging/magnetic resonance imaging. In patients who underwent subsequent parathyroidectomy, cure was based on lab values at least 6 months after surgery. Location-based sensitivity and specificity of 18F-fluorocholine positron emission tomography imaging was assessed using 3 anatomic locations (left neck, right neck, and mediastinum), with surgery as the gold standard.

Results: In 101 patients, 18F-fluorocholine positron emission tomography localized at least 1 candidate lesion in 93% of patients overall and in 91% of patients with previously negative imaging, leading to a change in preoperative strategy in 60% of patients. Of 76 patients who underwent parathyroidectomy, 58 (77%) had laboratory data at least 6 months postoperatively, with 55/58 patients (95%) demonstrating cure. 18F-fluorocholine positron emission tomography successfully guided curative surgery in 48/58 (83%) patients, compared with 20/57 (35%) based on ultrasound and 13/55 (24%) based on sestamibi. In a location-based analysis, sensitivity of 18F-fluorocholine positron emission tomography (88.9%) outperformed both ultrasound (37.1%) and sestamibi (27.5%), as well as ultrasound and sestamibi combined (47.8%).

Conclusion: Long-term results in the first cohort in the United States to use 18F-fluorocholine positron emission tomography for parathyroid localization confirm its utility in a challenging cohort, with better sensitivity than ultrasound or sestamibi.

Publication types

  • Clinical Trial, Phase II
  • Clinical Trial, Phase III
  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Choline / administration & dosage
  • Choline / analogs & derivatives*
  • Female
  • Fluorine Radioisotopes / administration & dosage
  • Humans
  • Hyperparathyroidism, Primary / diagnosis*
  • Hyperparathyroidism, Primary / etiology
  • Hyperparathyroidism, Primary / pathology
  • Hyperparathyroidism, Primary / surgery
  • Magnetic Resonance Imaging / statistics & numerical data
  • Male
  • Middle Aged
  • Parathyroid Glands / diagnostic imaging*
  • Parathyroid Glands / pathology
  • Parathyroid Glands / surgery
  • Parathyroid Neoplasms / complications
  • Parathyroid Neoplasms / diagnosis*
  • Parathyroid Neoplasms / pathology
  • Parathyroid Neoplasms / surgery
  • Parathyroidectomy / statistics & numerical data
  • Positron-Emission Tomography / methods*
  • Positron-Emission Tomography / statistics & numerical data
  • Preoperative Care / methods
  • Preoperative Care / statistics & numerical data
  • Technetium Tc 99m Sestamibi / administration & dosage
  • Treatment Outcome

Substances

  • Fluorine Radioisotopes
  • fluorocholine
  • Technetium Tc 99m Sestamibi
  • Choline